Drugs / anti-CD19 CAR-NK
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04639739 | Dec 2020 → Dec 2021 | B-cell non-Hodgkin lymphoma | Xinqiao Hospital of Chongqing | Unknown | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT06464861 | Jun 2024 → Jun 2026 overdue | mantle cell lymphoma, primary mediastinal large B-cell lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 1 | NCT05472558 | Jul 2022 → Dec 2025 overdue | B-cell non-Hodgkin lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 1 | NCT04887012 | May 2021 → May 2022 | B-cell non-Hodgkin lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD19 CAR NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04639739 ↗ |
| Known as | CAR-NK019 | “All subjects were intravenously administrated with CAR-NK019 at day 0 with a dose of 2x10\^6/kg” NCT06464861 ↗ |
| Modality | Cell therapy | “anti-CD19 CAR NK cell therapy” NCT04639739 ↗ |
| Route | Intravenous | “All subjects were intravenously administrated with CAR-NK019” NCT04887012 ↗ |
| Target | CD19 | “anti-CD19 CAR NK” NCT04639739 ↗ |